Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Pembrolizumab in Refractory Metastatic Triple Negative Breast Cancer
NCT05741164Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Sep 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in triple-negative breast cancer (TNBC), sponsored by Emory University. Primary endpoint: Objective Response at 6 months. Started Sep 2024; status: recruiting.
02
Drugs
propranolol
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05741164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741164.